Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

NCT00952380

Last updated date
Study Location
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Venous Thromboembolism
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-18
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

-

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


-

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Venous ThromboembolismDalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
NCT00445328
  1. Hyderabad, Andhra Pradesh
  2. Ahmedabad, Gujarat
  3. Trichur, Kerala
  4. Indore, Madhya Pradesh
  5. Chennai, Tamil Nadu
  6. Kolkata, West Bengal
  7. Kolkata, West Bengal
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Venous ThromboembolismAn Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®
NCT01046903
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Venous ThromboembolismFragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
NCT00952380
  1. Aurora, Colorado
  2. Washington, District of Columbia
  3. Jacksonville, Florida
  4. Jacksonville, Florida
  5. Tampa, Florida
  6. Tampa, Florida
  7. Tampa, Florida
  8. Tampa, Florida
  9. Tampa, Florida
  10. Detroit, Michigan
  11. Kansas City, Missouri
  12. Memphis, Tennessee
  13. El Paso, Texas
  14. El Paso, Texas
  15. Houston, Texas
  16. Houston, Texas
  17. Houston, Texas
  18. Oslo,
  19. Oslo,
  20. Kazan, Republic Tatarstan
  21. Kazan, Republic Tatarstan
  22. Moscow,
  23. Ljubljana,
  24. Ljubljana,
  25. Boadilla del Monte, Madrid
  26. Boadilla del Monte, Madrid
ALL GENDERS
0+
years
MULTIPLE SITES
Venous ThromboembolismApixaban for the Acute Treatment of Venous Thromboembolism in Children
NCT02464969
  1. Birmingham, Alabama
  2. Coimbra,
  3. Kyiv,
  4. Birmingham, Alabama
  5. Birmingham, Alabama
  6. Phoenix, Arizona
  7. Loma Linda, California
  8. Loma Linda, California
  9. Loma Linda, California
  10. Madera, California
  11. Oakland, California
  12. Oakland, California
  13. Oakland, California
  14. Palo Alto, California
  15. Palo Alto, California
  16. Palo Alto, California
  17. Roseville, California
  18. Sacramento, California
  19. Sacramento, California
  20. San Bernardino, California
  21. San Francisco, California
  22. San Francisco, California
  23. San Francisco, California
  24. Aurora, Colorado
  25. Aurora, Colorado
  26. Hartford, Connecticut
  27. Wilmington, Delaware
  28. Washington, District of Columbia
  29. Hollywood, Florida
  30. Hollywood, Florida
  31. Orlando, Florida
  32. Orlando, Florida
  33. Orlando, Florida
  34. Orlando, Florida
  35. Tampa, Florida
  36. West Palm Beach, Florida
  37. West Palm Beach, Florida
  38. Atlanta, Georgia
  39. Atlanta, Georgia
  40. Atlanta, Georgia
  41. Peoria, Illinois
  42. Indianapolis, Indiana
  43. Indianapolis, Indiana
  44. Indianapolis, Indiana
  45. Iowa City, Iowa
  46. Lexington, Kentucky
  47. New Orleans, Louisiana
  48. Boston, Massachusetts
  49. Ann Arbor, Michigan
  50. Detroit, Michigan
  51. Detroit, Michigan
  52. Jackson, Mississippi
  53. Hackensack, New Jersey
  54. New Brunswick, New Jersey
  55. New Brunswick, New Jersey
  56. New Brunswick, New Jersey
  57. New York, New York
  58. New York, New York
  59. New York, New York
  60. New York, New York
  61. New York, New York
  62. New York, New York
  63. Syracuse, New York
  64. Durham, North Carolina
  65. Durham, North Carolina
  66. Akron, Ohio
  67. Cincinnati, Ohio
  68. Cleveland, Ohio
  69. Cleveland, Ohio
  70. Columbus, Ohio
  71. Dayton, Ohio
  72. Oklahoma City, Oklahoma
  73. Oklahoma City, Oklahoma
  74. Philadelphia, Pennsylvania
  75. Philadelphia, Pennsylvania
  76. Philadelphia, Pennsylvania
  77. Philadelphia, Pennsylvania
  78. Pittsburgh, Pennsylvania
  79. Charleston, South Carolina
  80. Charleston, South Carolina
  81. Sioux Falls, South Dakota
  82. Sioux Falls, South Dakota
  83. Sioux Falls, South Dakota
  84. Sioux Falls, South Dakota
  85. Nashville, Tennessee
  86. Nashville, Tennessee
  87. Nashville, Tennessee
  88. Houston, Texas
  89. Houston, Texas
  90. Houston, Texas
  91. San Antonio, Texas
  92. San Antonio, Texas
  93. Salt Lake City, Utah
  94. Seattle, Washington
  95. Milwaukee, Wisconsin
  96. West Allis, Wisconsin
  97. Randwick, New South Wales
  98. Sydney, New South Wales
  99. Innsbruck, Tyrol
  100. Innsbruck,
  101. Wien,
  102. Hamilton, Ontario
  103. Ottawa, Ontario
  104. Berlin,
  105. Duisburg,
  106. Leipzig,
  107. Munchen,
  108. Beer Sheva,
  109. Beer Sheva,
  110. Beer Sheva,
  111. Haifa,
  112. Haifa,
  113. Ramat Gan,
  114. Lisboa,
  115. Kazan, Republic Tatarstan
  116. Yekaterinburg, Sverdlovsk Region
  117. Moscow,
  118. Moscow,
  119. Boadilla del Monte, Madrid
  120. Barcelona,
  121. Barcelona,
  122. Madrid,
  123. Dnipro,
  124. Zaporizhzhia,
  125. Glasgow, Scotland
  126. Newcastle upon Tyne, Tyne & Wear
  127. Cardiff, Wales
  128. Cardiff, Wales
  129. Birmingham, WEST Midlands
  130. Birmingham,
  131. Newcastle Upon Tyne,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Official Title  ICMJE A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN(REGISTERED) (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES
Brief Summary Three month treatment of acute VTE with Fragmin in pediatric cancer patients
Detailed Description Primary study objectives include are to determine the pharmacodynamic (PD) profiles for treatment doses of dalteparin in pediatric subjects of different ages with cancer and venous thromboembolism (VTE), using anti-Xa (Xa) levels and a population PD analysis methodology, and to determine the median dose required to achieve therapeutic anti- Xa levels (0.5 to 1.0 International Units [IU]/mL) based on subject age and weight.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Venous Thromboembolism
Intervention  ICMJE Drug: dalteparin
dalteparin subcutaneous injection
Study Arms  ICMJE Single Arm
Single arm open-label
Intervention: Drug: dalteparin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 9, 2018)
38
Original Estimated Enrollment  ICMJE
 (submitted: August 4, 2009)
50
Actual Study Completion Date  ICMJE March 2018
Actual Primary Completion Date March 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

-

Exclusion Criteria:

-

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE up to 18 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Norway,   Russian Federation,   Slovenia,   Spain,   United States
Removed Location Countries Croatia,   Germany,   Poland,   Romania
 
Administrative Information
NCT Number  ICMJE NCT00952380
Other Study ID Numbers  ICMJE FRAG-A001-201
A6301094 ( Other Identifier: Alias Study Number )
2016?000394?21 ( EudraCT Number )
2016-000394-21 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP